Equillium Stock Price, News & Analysis

Equillium, Inc. (Nasdaq: EQ) announced a public offering of 5 million shares at $7.00 per share, with potential proceeds of approximately $35 million. The offering includes a 30-day option for underwriters to purchase an additional 750,000 shares. Funds will support the development of product candidates, potential acquisitions, and general corporate purposes. The closing is anticipated on August 18, 2020. Jefferies, SVB Leerink, and Stifel serve as joint book-running managers.

Equillium, Inc. (Nasdaq: EQ) announced its intention to offer shares of its common stock in an underwritten public offering, aiming to sell shares exclusively from the company. Underwriters may purchase an additional 15% within 30 days. Proceeds will fund development of product candidates, potential acquisitions, and general corporate purposes. Jefferies, SVB Leerink, and Stifel are joint book-running managers. The offering is subject to market conditions, and details will be available in the prospectus supplement filed with the SEC.

Equillium, Inc. (Nasdaq: EQ) reported its Q2 2020 financial results, showcasing significant progress in its development of itolizumab for severe autoimmune disorders. Interim data from the EQUATE trial indicates a 71% complete response rate in acute graft-versus-host disease (aGVHD) patients. The company also highlighted positive results from Biocon's COVID-19 trial, leading to emergency use approval in India. Despite a net loss of $6.5 million, cash reserves stood at $42.6 million. Upcoming catalysts include new trials for itolizumab in COVID-19 and other conditions.

Equillium (Nasdaq: EQ) announced positive interim results from the EQUATE study involving itolizumab for treating acute graft-versus-host disease (aGVHD). In the first two cohorts, five of seven patients achieved complete responses, with a 71% overall response rate. Itolizumab has been well tolerated, prompting plans for dose escalation. Additionally, a Pre-IND meeting request has been submitted to the FDA to explore itolizumab’s use in COVID-19 patients, building on supportive data from Biocon’s studies. This underscores Equillium’s commitment to developing innovative therapies for severe autoimmune conditions.

Equillium, a clinical-stage biotechnology firm, announced that CEO Bruce Steel and CMO Krishna Polu will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 3:30 PM ET. The discussion will focus on developing treatments for severe autoimmune disorders, including their lead candidate, itolizumab, a monoclonal antibody targeting the CD6-ALCAM pathway. Itolizumab has shown promise in various conditions and has received emergency authorization in India for managing cytokine release syndrome in COVID-19 patients. For more information, visit www.equilliumbio.com.

Equillium announced significant findings from a clinical trial conducted by Biocon in India, demonstrating that itolizumab reduced mortality rates in COVID-19 patients with moderate to severe ARDS. The India's Drug Controller General approved itolizumab for emergency use against cytokine release syndrome associated with COVID-19. Following these positive topline results, Equillium is set to launch a global randomized controlled trial under a U.S. investigational new drug application, aiming to further validate itolizumab’s efficacy.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, announced that CEO Bruce Steel and CMO Krishna Polu will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 PM ET. This presentation will focus on Equillium's innovative efforts in treating severe autoimmune and inflammatory disorders, particularly through its product candidate itolizumab (EQ001). The live webcast can be accessed on the company’s website and will be available for replay for 30 days.

Equillium, Inc. (Nasdaq: EQ) reported its first quarter 2020 financial results, revealing a net loss of $7.8 million, equating to $(0.45) per share, which is an increase compared to a $6.0 million loss or $(0.34) per share in Q1 2019. R&D expenses rose to $4.7 million, driven by clinical trial activities, while G&A expenses slightly increased to $2.7 million. Equillium's cash and equivalents amounted to $47.7 million, down from $53.1 million at the end of 2019. The company paused some clinical trials due to the COVID-19 pandemic but expects initial data from the EQUATE trial in the second half of 2020.

Equillium (Nasdaq: EQ), a biotechnology firm, will participate in the 2020 RBC Capital Markets Virtual Global Healthcare Conference on May 20, 2020. The discussion will include CEO Bruce Steel and CMO Krishna Polu, starting at 3:05 PM ET. The event will be broadcast live, and replays will be available for 30 days. Equillium is focused on developing itolizumab, a first-in-class monoclonal antibody targeting the CD6-ALCAM pathway, aimed at treating severe autoimmune and inflammatory disorders.